Prolaktin
Kod:9017|CPT:84146|LOINC:2842-3
| Kabi | Prolaktin |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Elektrokimyoluminessent immunoanaliz (ECLIA)
Kutilayotgan natija topshirish vaqti
1 kun
Maxsus tayyorlik
- Infants younger than 1 year: avoid feeding for 30–40 minutes before the blood draw.
- Children 1–5 years: do not give food for 2–3 hours before collection.
- Older children and adults: refrain from eating for 2–3 hours before collection; water is allowed.
- If clinically acceptable, hold steroid and thyroid hormone medications for 48 hours before collection.
- Limit physical and emotional stress during the 24 hours before the test.
- Do not smoke during the 3 hours preceding collection.
- If taking high-dose biotin (>5 mg/day), collect the specimen at least 8 hours after the last dose.
Qanday foydalanish
Prolaktin (PRL) testi, laktotrop gormon yoki mammotropin miqdorini o'lchash sifatida ham tanilgan, galaktoreya va amenoreya yoki anovulyatsiya kabi hayz ko'rish buzilishlari uchun birinchi qator laboratoriya tekshiruvidir. Prolaktin ajratuvchi adenoma gumon qilinganda, u mikroadenoma yoki makroadenoma bo'lishidan qat'i nazar va sellar tasvirlashda o'zgarishlar aniqlanishi-aniqlanmasligidan qat'i nazar, gipofiz funksiyasini baholash uchun qo'llaniladi. O'lchash bepushtlik va jinsiy disfunktsiyani, shu jumladan erkaklarda gipogonadizmni tekshirishning ajralmas qismidir va davolash davomida tasdiqlangan prolaktinomasi bo'lgan bemorlarni monitoring qilishda qo'llaniladi. Prolaktinning ko'tarilishi sariq tana yetishmovchiligi yoki anovulyatsiya bilan birga kechishi mumkin. Surunkali giperprolaktinemiya amenoreya, anovulyatsiya va suyak zichligining pasayishiga olib kelishi mumkin.
Cheklovlar
Prolaktin (PRL) sekretsiyasi pulsatil tarzda sodir bo'ladi va sirkadiyal naqshga amal qiladi; emizish va stress fiziologik oshishini chaqiradi. Konsentrasiyalar homiladorlik va postpartum davrda laktatsiyani qo'llab-quvvatlash uchun ko'tariladi, so'ng emizish to'xtatilgach kamayadi. Prolaktin ajratuvchi gipofiz adenomalari patologik giperprolaktinemiyaning keng uchraydigan sababidir. O'smalar kattalashganda, ular bosh og'rig'i va ko'rishning buzilishi kabi massa effektlarini keltirib chiqarishi va boshqa gipofiz gormonlari sekretsiyasini izdan chiqarishi mumkin, bu ayollarda bepushtlikka va erkaklarda gipogonadizmga hissa qo'shadi.
| O'lchov birligi | ng/mL | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Referens oraliq |
| |||||||||
| Ko'rsatmalar | Clinical features suggestive of a prolactinoma, including headaches, visual field loss, or galactorrhea, Workup of infertility or sexual dysfunction, Assessment of male hypogonadism in the context of low testosterone, Follow-up and management of a confirmed prolactinoma, Evaluation of suspected hypopituitarism in conjunction with growth hormone testing, Surveillance in patients taking medications that alter dopaminergic activity |
Natija og'ishlarining mumkin sabablari
Oshgan daraja
- amphetamines
- anorexia nervosa
- breastfeeding
- chronic kidney disease
- dibenzodiazepines
- estrogen therapy
- hypothalamic disorders
- hypothyroidism
- methyldopa
- opiates
- phenothiazines
- pituitary neoplasms (nonprolactinoma)
- pregnancy
- reserpine
- stress
- trh administration
- tricyclic antidepressants
- verapamil
Pasaygan daraja
- biotin (high dose)
- dopamine
- ergotamine derivatives
- levodopa
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 1 mL (min 0.7 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Baskin HJ. Endocrinologic evaluation of impotence. South Med J. 1989 Apr;82(4):446-449. PubMed 2495570 Berczi I, Cosby H, Hunter T, Baragar F, McNeilly AS, Friesen HG. Decreased bioactivity of circulating prolactin in patients with rheumatoid arthritis. Br J Rheumatol. 1987 Dec;26(6):433-436. PubMed 3690137 Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med. 1981 Jan 15;304(3):156-158. PubMed 7442734 Fujimoto VY, Clifton DK, Cohen NL, Soules MR. Variability of serum prolactin and progesterone levels in normal women: The relevance of single hormone measurements in the clinical setting. Obstet Gynecol. 1990 Jul;76(1):71-78. PubMed 2359568 Kelly PA, Djiane J, Postel-Vinay MC, Edery M. The prolactin/growth hormone receptor family. Endocr Rev. 1991 Aug;12(3):235-251. PubMed 1935820 Kletzky OA, Davajan V. Hyperprolactinemia: Diagnosis and treatment. In: Mishell DR Jr, Davajan V, eds. Infertility, Contraception and Reproductive Endocrinology. 2nd ed. Oradell, NJ: Medical Economics Books;1986:275-301. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A. The natural history of untreated hyperprolactinemia: A prospective analysis. J Clin Endocrinol Metab. 1989 Feb;68(2):412-418. PubMed 2918052 Smith CR, Butler J, Hashim I, Norman MR. Serum prolactin bioactivity and immunoactivity in hyperprolactinaemic states. Ann Clin Biochem. 1990 Jan;27(Pt 1):3-8. PubMed 2310154 Tippet PD, Simon JA, Rifka SM, Falk RJ. Luteal phase hyperprolactinemia during ovulation induction with human menopausal gonadotropins: Incidence, recurrence, and effect on pregnancy rates. Obstet Gynecol. 1989 Apr;73(4):613-616. PubMed 2494621 Veldhuis JD, Evans WS, Stumpf PG. Mechanisms that subserve estradiol's induction of increased prolactin concentrations: Evidence of amplitude modulation of spontaneous prolactin secretory bursts. Am J Obstet Gynecol. 1989 Nov;161(5):1149-1158. PubMed 2589434